The role of TRAIL (TNFSF10) expression as a predictor of clinical outcome in patients with metastatic RCC treated with inhibitory agents for tyrosine kinase and/or mTOR in the Cancer Institute Hospital was investigated. The gene discussed is TNFSF10; the disease is renal cell carcinoma.